Berkeley, CA, United States of America

Melissa J Leyva

This inventor holds 2 USPTO granted patents. Top assignees: Buck Institute for Research on Aging, University of California. Active years: 2013-2016.


% Patents Active = 50.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2013-2016

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Melissa J Leyva: Innovator in Caspase Inhibitors

Introduction

Melissa J Leyva is a prominent inventor based in Berkeley, CA. She has made significant contributions to the field of biomedical research, particularly in the development of caspase inhibitors. With a total of 2 patents, her work focuses on innovative solutions for treating various pathologies.

Latest Patents

Leyva's latest patents include groundbreaking inventions related to caspase inhibitors. These inventions provide novel caspase inhibitors that are useful for the prophylaxis or treatment of several pathologies, including Huntington's disease. In certain embodiments, the inhibitors include inhibitors of caspase-3 and/or caspase-6, showcasing her commitment to advancing medical science.

Career Highlights

Throughout her career, Melissa has worked with esteemed institutions such as the Buck Institute for Research on Aging and the University of California. Her research has been pivotal in understanding the role of caspases in various diseases, contributing to the development of therapeutic strategies.

Collaborations

Melissa has collaborated with notable colleagues, including Jonathan A Ellman and Lisa M Ellerby. These partnerships have enhanced her research and expanded the impact of her inventions in the scientific community.

Conclusion

Melissa J Leyva is a remarkable inventor whose work in caspase inhibitors is paving the way for new treatments in medicine. Her dedication to research and innovation continues to inspire advancements in the field.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…